1-3 of 3
François Mullier, PhD
Close
Sort by
Journal Articles

Dabigatran Etexilate and Risk Of Myocardial Infarction, Major Bleeding and All-Cause Mortality: A Systematic Review and Meta-Analysis Of Randomized Controlled Trials

Jonathan Douxfils, Pharm D, PhD Student, Fanny Buckinx, François Mullier, PhD, Valentine Minet, Pharm D, PhD Student, Véronique Rabenda, Jean-Yves Reginster, Professor, Christian Chatelain, Professor, Philippe Hainaut, Professor, Olivier Bruyère, Professor, Jean-Michel Dogné, Professor
Journal: Blood
Blood (2013) 122 (21): 3633.
https://doi.org/10.1182/blood.V122.21.3633.3633
Published: 2013
Journal Articles

Is Dilute Russell’s Viper Venom Time a Useful Assay To Monitor Patients Treated By Rivaroxaban Or Dabigatran Etexilate?

Jonathan Douxfils, Pharm D, PhD Student, Anne Tamigniau, Pharm D, Bernard Chatelain, Professor, Bérangère Devalet, M.D., Pierre Wallemacq, Professor, Paul Hjemdahl, Professor, Yuko Rönquist-Nii, Jean-Michel Dogné, Professor, François Mullier, PhD
Journal: Blood
Blood (2013) 122 (21): 3634.
https://doi.org/10.1182/blood.V122.21.3634.3634
Published: 2013
Journal Articles

What Is The Best Time Sampling For The Two Direct Oral Anticoagulants, Dabigatran and Rivaroxaban?

Jonathan Douxfils, Pharm D, PhD, Jean-Francois Classen, Pharm.Biol., Justine Baudar, Bérangère Devalet, M.D., Meyer Michel Samama, Bernard Chatelain, Jean-Michel Dogné, François Mullier, PhD
Journal: Blood
Blood (2013) 122 (21): 4805.
https://doi.org/10.1182/blood.V122.21.4805.4805
Published: 2013